Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 22, 2024

Intrinsic Subtype and Overall Survival in Advanced HR+/HER2− Breast Cancer Treated With Ribociclib and Endocrine Therapy

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Intrinsic subtype and overall survival of patients with advanced HR+/HER2- breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7
Clin. Cancer Res 2023 Nov 08;[EPub Ahead of Print], A Prat, N Solovieff, F Andre, J O'Shaughnessy, DA Cameron, W Janni, GS Sonke, YS Yap, DA Yardley, AH Partridge, A Thuerigen, JP Zarate, A Lteif, F Su, LA Carey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading